P-097 Hepatic artery embolization (HAE) in hepatocellular and gastroenteropancreatic neuroendocrine tumors at Instituto Oncologico Nacional, Panama

Castillo-Fernandez, Omar; Tapia, Héctor; Ruiz, M.; Llerena, Jose Pinto; Lim, Maria; Pereira, Yamileth; Montano, Lilian; Cukier, Moisés

doi:10.1093/annonc/mdw199.92

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, prophylaxis was only used in 20.1% of the whole population (1,116/5,545). The employed prophylaxis included octreotide therapy (13 studies) [39, 61, 64, 65, 83, 92, 100, 102, 104, 111, 122, 128, 129] and somatostatin analogues (not specified; 2 studies) [99, 132]; however, in 86 studies, prophylaxis details were not reported.…”

Section: Resultsmentioning

confidence: 99%

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

Kanabar

Barriuso

McNamara³

et al. 2020

Neuroendocrinology

View full text Add to dashboard Cite

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs. Methods: Eligible studies (identified using MED-LINE-PubMed) were those reporting data on NEN patients who had undergone any type of liver embolisation. The primary end points were best radiological response and symptomatic response; secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity. Results: Of 598 studies screened, 101 were eligible: 16 were prospective (15.8%). The eligible studies included a total of 5,545 NEN patients, with a median of 39 patients per study (range 5-214). Pooled rate of partial response was 36.6% (38.9% achieved stable disease) and 55.2% of patients had a symptomatic response to therapy when pooled data were analysed. The median PFS and OS were 18.4 months (95% CI 15.5-21.2) and 40.7 months (95% CI 35.2-46.2) respectively. The most common toxicities were found to be abdominal pain (48.8%) and nausea (48.1%). Outcome did not significantly vary depending on the type of embolisation performed. Conclusion: Liver embolisation provides adequate symptom relief for patients with carcinoid syndrome and is also able to reach partial response in a significant proportion of patients and a reasonable PFS. Quality of studies was limited, highlighting the need of further prospective studies to confirm the most suitable form of liver embolisation in NENs.

show abstract